Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pharming Group's Revenue for the
three
months ended in Mar. 2026 was $72.4 Mil. Pharming Group's average Accounts Receivable for the
three
months ended in Mar. 2026 was $50.9 Mil.
Hence, Pharming Group's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.42.
Pharming Group (NAS:PHAR) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pharming Group Receivables Turnover Related Terms
Pharming Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pharming Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAR vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Pharming Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pharming Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a Receivables Turnover of 1.42 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #282 out of 841 companies in the Biotechnology industry, placing it in the top 33.5%.
Is Pharming Group's Receivables Turnover too high?
Pharming Group's current Receivables Turnover is 1.42. The Biotechnology industry median Receivables Turnover is 5.29. Pharming Group's value of 1.42 is 73.2% below this industry median. Based on the distribution chart, Pharming Group ranks #282 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #282 out of 841 companies for Receivables Turnover. This puts Pharming Group in the upper half of its industry. The industry median Receivables Turnover is 5.29. Pharming Group's value of 1.42 is 73.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current Receivables Turnover of 1.42 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Receivables Turnover is 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.72, compared to a current price of $13.40 — trading 9% below its estimated fair value. The current Receivables Turnover is 1.42 and 73.2% below the Biotechnology industry median of 5.29. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pharming Group (PHAR), the current Receivables Turnover is 1.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.40 is trading 9% below its estimated GF Value™ of $14.72.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Receivables Turnover: 1.42
GF Value™: $14.72 vs. price of $13.40 (9% below fair value)
Industry Position: 73.2% below the Biotechnology median (#282 of 841)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score
Get the complete analysis for PHAR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
